Literature DB >> 31877321

Anti-neuroinflammatory, protective effects of the synthetic microneurotrophin BNN-20 in the advanced dopaminergic neurodegeneration of "weaver" mice.

Vasiliki Panagiotakopoulou1, Konstantinos Botsakis2, Foteini Delis3, Theodora Mourtzi1, Manolis N Tzatzarakis4, Aggeliki Dimopoulou2, Nafsika Poulia3, Katerina Antoniou3, Georgios T Stathopoulos2, Nikolaos Matsokis1, Ioannis Charalampopoulos5, Achilleas Gravanis5, Fevronia Angelatou6.   

Abstract

BNN-20 is a synthetic microneurotrophin, long-term (P1-P21) administration of which exerts potent neuroprotective effect on the "weaver" mouse, a genetic model of progressive, nigrostriatal dopaminergic degeneration. The present study complements and expands our previous work, providing evidence that BNN-20 fully protects the dopaminergic neurons even when administration begins at a late stage of dopaminergic degeneration (>40%). Since neuroinflammation plays a critical role in Parkinson's disease, we investigated the possible anti-neuroinflammatory mechanisms underlying the pharmacological action of BNN-20. The latter was shown to be microglia-mediated, at least in part. Indeed, BNN-20 induced a partial, but significant, reversal of microglia hyperactivation, observed in the untreated "weaver" mouse. Furthermore, it induced a shift in microglia polarization towards the neuroprotective M2 phenotype, suggesting a possible beneficial shifting of microglia activity. This observation was further supported by morphometric measurements. Moreover, BDNF levels, which were severely reduced in the "weaver" mouse midbrain, were restored to normal even after short-term BNN-20 administration. Experiments in "weaver"/NGL (dual GFP/luciferase-NF-κВ reporter) mice using bioluminescence after a short BNN-20 treatment (P60-P74), have shown that the increase of BDNF production was specifically mediated through the TrkB-PI3K-Akt-NF-κB signaling pathway. Interestingly, long-term BNN-20 treatment (P14-P60) significantly increased dopamine levels in the "weaver" striatum, which seems to be associated with the improved motor activity observed in the treated mutant animals. In conclusion, our findings suggest that BNN-20 may serve as a lead molecule for new therapeutic compounds for Parkinson's disease, combining strong anti-neuroinflammatory and neuroprotective properties, leading to elevated dopamine levels and improved motor activity.
Copyright © 2019. Published by Elsevier Ltd.

Entities:  

Keywords:  BDNF production; Microglia-polarization; Microneurotrophin; Neuroprotection

Year:  2019        PMID: 31877321     DOI: 10.1016/j.neuropharm.2019.107919

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  4 in total

Review 1.  Endogenous versus exogenous cell replacement for Parkinson's disease: where are we at and where are we going?

Authors:  Theodora Mourtzi; Ilias Kazanis
Journal:  Neural Regen Res       Date:  2022-12       Impact factor: 6.058

2.  Quantification of BNN27, a novel neuroprotective 17-spiroepoxy dehydroepiandrosterone derivative in the blood and retina of rodents, after single intraperitoneal administration.

Authors:  Chrysanthi Tsika; Manolis N Tzatzarakis; Sophia G Antimisiaris; Pavlina Tsoka; Paschalis Efstathopoulos; Ioannis Charalampopoulos; Achille Gravanis; Miltiadis K Tsilimbaris
Journal:  Pharmacol Res Perspect       Date:  2021-04

Review 3.  Disease-Modifying Therapies for Multiple System Atrophy: Where Are We in 2022?

Authors:  Victoria Sidoroff; Pam Bower; Nadia Stefanova; Alessandra Fanciulli; Iva Stankovic; Werner Poewe; Klaus Seppi; Gregor K Wenning; Florian Krismer
Journal:  J Parkinsons Dis       Date:  2022       Impact factor: 5.520

4.  Characterization of substantia nigra neurogenesis in homeostasis and dopaminergic degeneration: beneficial effects of the microneurotrophin BNN-20.

Authors:  Dimitrios Dimitrakopoulos; Dimitrios Kakogiannis; Fevronia Angelatou; Ilias Kazanis; Theodora Mourtzi; Charalampos Salodimitris; Konstantinos Botsakis; Danai Kassandra Meri; Maria Anesti; Aggeliki Dimopoulou; Ioannis Charalampopoulos; Achilleas Gravanis; Nikolaos Matsokis
Journal:  Stem Cell Res Ther       Date:  2021-06-10       Impact factor: 6.832

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.